Evaluating a Targeted Cancer Therapy Approach Mediated by RNA

Animals Cell Line Cell Survival / drug effects Disease Management Disease Models, Animal Disease Susceptibility Epidermolysis Bullosa / complications Epidermolysis Bullosa Dystrophica / complications Ganciclovir / pharmacology Gene Expression Regulation / drug effects Genetic Loci Genetic Therapy / adverse effects Humans Mice RNA Splicing Skin Neoplasms / diagnosis Trans-Splicing Xenograft Model Antitumor Assays
Ct-SLCO1B3 cancer gene therapy epidermolysis bullosa ganciclovir herpes simplex virus thymidine kinase spliceosome mediated RNA trans-splicing squamous cell carcinoma

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
05 Jan 2022
Historique:
received: 28 10 2021
revised: 20 12 2021
accepted: 24 12 2021
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 5 2 2022
Statut: epublish

Résumé

Conventional anti-cancer therapies based on chemo- and/or radiotherapy represent highly effective means to kill cancer cells but lack tumor specificity and, therefore, result in a wide range of iatrogenic effects. A promising approach to overcome this obstacle is spliceosome-mediated RNA

Identifiants

DOI: 10.3390/ijms23010575 PMID: 35008999 PMC: PMC8745581
pubmed: 35008999
pii: ijms23010575
doi: 10.3390/ijms23010575
pmc: PMC8745581
pii:
doi:

Substances chimiques

Ganciclovir P9G3CKZ4P5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Paracelsus Medical University
ID : E-14/19/098GRU

Références

Trends Cancer. 2016 Sep;2(9):475-484
pubmed: 28210711
Curr Opin Genet Dev. 2018 Feb;48:36-43
pubmed: 29100211
Mol Genet Metab. 2003 Sep-Oct;80(1-2):148-58
pubmed: 14567964
Drug Metab Lett. 2018;12(1):24-32
pubmed: 29577869
Adv Drug Deliv Rev. 2021 Sep;176:113842
pubmed: 34293384
Acta Derm Venereol. 2018 Jan 12;98(1):70-76
pubmed: 28853495
Mol Ther Nucleic Acids. 2018 Sep 7;12:294-308
pubmed: 30195768
JAMA Dermatol. 2016 Nov 1;152(11):1231-1238
pubmed: 27463098
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9172-7
pubmed: 21571633
J Invest Dermatol. 2008 Mar;128(3):568-74
pubmed: 17989727
Nucleic Acids Res. 2017 Sep 29;45(17):10259-10269
pubmed: 28973459
Nat Rev Dis Primers. 2020 Sep 24;6(1):78
pubmed: 32973163
Annu Rev Biomed Eng. 2000;2:289-313
pubmed: 11701514
Mol Cancer Ther. 2011 Feb;10(2):233-41
pubmed: 21209069
Front Neurosci. 2017 Oct 10;11:544
pubmed: 29066943
Mol Ther Nucleic Acids. 2016 Sep 13;5(9):e362
pubmed: 27623444
Cancer Lett. 2018 Oct 1;433:107-116
pubmed: 29960051
Int J Mol Sci. 2016 Sep 22;17(10):
pubmed: 27669223
Nat Med. 2004 Aug;10(8):835-41
pubmed: 15273748
Mol Pharm. 2013 Jan 7;10(1):406-16
pubmed: 23215050
Mol Ther. 2003 Sep;8(3):495-500
pubmed: 12946323
Br Med Bull. 2020 Dec 15;136(1):4-20
pubmed: 33010155
Nature. 1997 Sep 18;389(6648):239-42
pubmed: 9305836
Gene Ther. 2016 Nov;23(11):775-784
pubmed: 27434145
Biochem Biophys Res Commun. 2012 Feb 24;418(4):818-23
pubmed: 22326869
Mol Ther Nucleic Acids. 2016 Mar 01;5:e287
pubmed: 26928235
Nucleic Acids Res. 2011 Sep 1;39(16):e108
pubmed: 21685452
J Invest Dermatol. 2018 May;138(5):1197-1200
pubmed: 29203361
Sci Transl Med. 2018 Aug 22;10(455):
pubmed: 30135250
Nat Med. 2003 Aug;9(8):1015-9
pubmed: 12847523
Cancer Lett. 2008 Nov 8;270(2):191-201
pubmed: 18502571
Eur J Dermatol. 2015 Apr;25 Suppl 1:30-2
pubmed: 26083672
Nat Biotechnol. 2002 Jan;20(1):47-52
pubmed: 11753361
Genome Biol Evol. 2016 Mar 10;8(3):562-77
pubmed: 26966239
Virology. 1988 Apr;163(2):638-42
pubmed: 2833027
Curr Gene Ther. 2003 Feb;3(1):13-26
pubmed: 12553532
Br J Dermatol. 2019 Jan;180(1):141-148
pubmed: 30099737
Nat Biotechnol. 1999 Mar;17(3):246-52
pubmed: 10096291
Mol Ther Nucleic Acids. 2017 Jun 16;7:140-154
pubmed: 28624190
Oncotarget. 2018 Aug 14;9(63):32182-32190
pubmed: 30181808
Mol Oncol. 2013 Dec;7(6):1056-68
pubmed: 23998959
Mol Ther Nucleic Acids. 2018 Jun 1;11:41-56
pubmed: 29858076
J Am Acad Dermatol. 2009 Feb;60(2):203-11
pubmed: 19026465
Cell. 1978 Sep;15(1):245-50
pubmed: 699044
J Invest Dermatol. 2011 Jan;131(1):74-83
pubmed: 20720561

Auteurs

Katharina Woess (K)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
ORCID: 0000-0001-6189-2733

Yuchen Sun (Y)

Division of Medicinal Safety Science, National Institute of Health Sciences, Kanagawa 210-9501, Japan.
ORCID: 0000-0001-5452-8829

Hanae Morio (H)

Laboratory of Clinical Pharmacy and Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0355, Japan.

Anna Stierschneider (A)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.

Anna Kaufmann (A)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.

Stefan Hainzl (S)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.

Lisa Trattner (L)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.

Thomas Kocher (T)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
ORCID: 0000-0002-3424-3049

Birgit Tockner (B)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.

Victoria Leb-Reichl (V)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.

Markus Steiner (M)

Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.

Gabriele Brachtl (G)

Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, 5020 Salzburg, Austria.

Andrew P South (AP)

Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Johann W Bauer (JW)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.

Julia Reichelt (J)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
ORCID: 0000-0002-4358-7011

Tomomi Furihata (T)

Laboratory of Clinical Pharmacy and Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0355, Japan.

Verena Wally (V)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
ORCID: 0000-0001-8705-3890

Ulrich Koller (U)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
ORCID: 0000-0002-6285-1789

Josefina Piñón Hofbauer (J)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
ORCID: 0000-0002-8558-9031

Christina Guttmann-Gruber (C)

EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
ORCID: 0000-0001-8232-5068

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Administration des services de santé › Gestion des soins aux patients › Prise en charge de la maladie › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Phénomènes physiologiques › Constitution physique › Prédisposition aux maladies › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses vésiculobulleuses › Épidermolyse bulleuse › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses vésiculobulleuses › Épidermolyse bulleuse › Épidermolyse bulleuse dystrophique › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Purines › Purinones › Hypoxanthines › Guanine › Aciclovir › Ganciclovir › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Locus génétiques › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Génie génétique › Thérapie génétique › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Maturation post-transcriptionnelle des ARN › Épissage des ARN › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Maturation post-transcriptionnelle des ARN › Épissage des ARN › Épissage en trans › Evaluating a Targeted Cancer Therapy Approach...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Evaluating a Targeted Cancer Therapy Approach...